Invivoscribe Reports Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

Invivoscribe^® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has signed a long-term strategic collaboration agreement with Thermo Fisher Scientific to develop multiple next-generation sequencing (NGS)-based, in vitro diagnostic (IVD) oncology tests on the Ion PGM™ Dx System.
According to the press release:

Under terms of the agreement, Invivoscribe will leverage its more than two decades of development, validation and commercialization experience to manufacture and commercialize immuno-oncology molecular diagnostics and associated bioinformatics software for application in liquid biopsies. The assays may become powerful tools for diagnosis and minimal residual disease (MRD) monitoring of the full range of hematologic malignancies..

Joe Bernardo, president of Clinical Sequencing at Thermo Fisher said:

As the world leader in serving science, Thermo Fisher is committed to collaborating with strategic partners who share our drive to help make precision medicine a reality. We look forward to providing our expertise and next-generation sequencing diagnostic system, which will serve as the foundational platform for an expanding line of Invivoscribe NGS oncology assays.

Click here to view the full press release.